Drugs / C-IVIG
C-IVIG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04521309 | Jun 2020 → Jan 2021 | COVID-19 | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04891172 | Aug 2021 → Dec 2022 | COVID-19 | Dow University of Health Sciences | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-IVIG | “Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial.” PMID 34109306 ↗ Jun 2021 |
| Known as | Anti COVID 19 Intravenous Immunoglobulin | “Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)” NCT04891172 ↗ |
| Known as | Hyperimmune anti-COVID-19 IVIG | “Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial.” PMID 34109306 ↗ Jun 2021 |
| Modality | Protein / enzyme biologic | “Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG) is an unexplored therapy” PMID 34109306 ↗ Jun 2021 |
| Route | Intravenous | “This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.” NCT04521309 ↗ |